JPWO2020232173A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020232173A5 JPWO2020232173A5 JP2021567963A JP2021567963A JPWO2020232173A5 JP WO2020232173 A5 JPWO2020232173 A5 JP WO2020232173A5 JP 2021567963 A JP2021567963 A JP 2021567963A JP 2021567963 A JP2021567963 A JP 2021567963A JP WO2020232173 A5 JPWO2020232173 A5 JP WO2020232173A5
- Authority
- JP
- Japan
- Prior art keywords
- formulated
- drug
- use according
- administration
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025133004A JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847825P | 2019-05-14 | 2019-05-14 | |
| US62/847,825 | 2019-05-14 | ||
| US201962860739P | 2019-06-12 | 2019-06-12 | |
| US62/860,739 | 2019-06-12 | ||
| US201962899088P | 2019-09-11 | 2019-09-11 | |
| US62/899,088 | 2019-09-11 | ||
| EP20305223 | 2020-03-03 | ||
| EP20305223.8 | 2020-03-03 | ||
| PCT/US2020/032754 WO2020232173A1 (en) | 2019-05-14 | 2020-05-13 | Methods of administering anti-cd38 antibody to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133004A Division JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532356A JP2022532356A (ja) | 2022-07-14 |
| JP2022532356A5 JP2022532356A5 (https=) | 2023-05-22 |
| JPWO2020232173A5 true JPWO2020232173A5 (https=) | 2023-05-22 |
| JP7801132B2 JP7801132B2 (ja) | 2026-01-16 |
Family
ID=71094805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567963A Active JP7801132B2 (ja) | 2019-05-14 | 2020-05-13 | 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法 |
| JP2025133004A Pending JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133004A Pending JP2025166108A (ja) | 2019-05-14 | 2025-08-08 | 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210171650A1 (https=) |
| EP (1) | EP3969004A1 (https=) |
| JP (2) | JP7801132B2 (https=) |
| KR (1) | KR20220008305A (https=) |
| CN (2) | CN114080233A (https=) |
| AU (1) | AU2020274169A1 (https=) |
| BR (1) | BR112021022503A2 (https=) |
| CA (1) | CA3140034A1 (https=) |
| CO (1) | CO2021016606A2 (https=) |
| IL (1) | IL287832A (https=) |
| MA (1) | MA55967A (https=) |
| MX (1) | MX2021013910A (https=) |
| SG (1) | SG11202112513YA (https=) |
| TW (1) | TW202108624A (https=) |
| WO (1) | WO2020232173A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| KR20210006321A (ko) | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| TW202019962A (zh) * | 2018-07-10 | 2020-06-01 | 法商賽諾菲公司 | 標靶CD38及TGF-β的組合療法 |
| CN113993543B (zh) * | 2019-06-10 | 2024-07-12 | 武田药品工业株式会社 | 使用抗cd38抗体的组合疗法 |
| IL302640A (en) * | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| AU2022253256A1 (en) * | 2021-04-08 | 2023-11-16 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd38-targeted antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US11939390B2 (en) * | 2019-01-28 | 2024-03-26 | Sanofi-Aventis U.S. Llc | Methods of treating multiple myeloma |
-
2020
- 2020-05-13 US US15/931,466 patent/US20210171650A1/en active Pending
- 2020-05-13 AU AU2020274169A patent/AU2020274169A1/en active Pending
- 2020-05-13 SG SG11202112513YA patent/SG11202112513YA/en unknown
- 2020-05-13 EP EP20733081.2A patent/EP3969004A1/en active Pending
- 2020-05-13 KR KR1020217040398A patent/KR20220008305A/ko active Pending
- 2020-05-13 BR BR112021022503A patent/BR112021022503A2/pt unknown
- 2020-05-13 MX MX2021013910A patent/MX2021013910A/es unknown
- 2020-05-13 WO PCT/US2020/032754 patent/WO2020232173A1/en not_active Ceased
- 2020-05-13 MA MA055967A patent/MA55967A/fr unknown
- 2020-05-13 CA CA3140034A patent/CA3140034A1/en active Pending
- 2020-05-13 CN CN202080049892.8A patent/CN114080233A/zh active Pending
- 2020-05-13 JP JP2021567963A patent/JP7801132B2/ja active Active
- 2020-05-13 CN CN202510468038.XA patent/CN120501855A/zh active Pending
- 2020-05-14 TW TW109116104A patent/TW202108624A/zh unknown
-
2021
- 2021-11-04 IL IL287832A patent/IL287832A/en unknown
- 2021-12-07 CO CONC2021/0016606A patent/CO2021016606A2/es unknown
-
2025
- 2025-08-08 JP JP2025133004A patent/JP2025166108A/ja active Pending